Introduction
We and others have demonstrated that interleukin-6 (IL-6) is a growth (Hallek et al., 1998; Kawano et al., 1988; Klein et al., 1989 Klein et al., , 1995 and anti-apoptotic (Chauhan et al., 1997a,b,c; Lichtenstein et al., 1995) factor in human multiple myeloma (MM) cells and characterized the signaling cascades mediating these eects. For example, IL-6 induces proliferation of MM cells via activation of the Ras/Raf/MEK/MAPK signaling pathway (Ogata et al., 1997) , whereas the JAK/STAT3 signaling pathway promotes MM cell survival (Catlett-Falcone et al., 1999) . In addition, we and others have shown that IL-6 protects against Dexinduced apoptosis (Chauhan et al., 1997b; Hardin et al., 1994; Lichtenstein et al., 1995) . Speci®cally, our studies show that Dex-induced apoptosis in MM cells is mediated via Related adhesion focal tyrosine kinase (RAFTK) activation (Chauhan et al., 1999) ; conversely, IL-6 confers protection against Dex-induced apoptosis via activation of SH2 domain containing protein tyrosine kinase SHP2 (also known as SH-PTP2 and PTP1D), which binds and dephosphorylates RAFTK (Chauhan et al., 2000) . IL-6 also activates phosphatidylinositol 3-kinase (PI3-K) and downstream protein kinase Akt/PKB in prostate cancer cells (Chung et al., 2000; Qiu et al., 1998) , hepatoma cells (Chen et al., 1999) , and in MM cells (Tu et al., 2000) , but the role of PI3-K/Akt signaling in mediating the sequelae of IL-6 in MM is not fully characterized.
Akt is a serine (Ser)/threonine (Thr) protein kinase which resides within the cytosol in a catalytically inactive state in quiescent or serum-starved cells. After stimulation of cells with growth factors and cytokines such as insulin-like growth factor (IGF), plateletderived growth factor (PDGF), vascular endothelial growth factor (VEGF), IL-2, IL-3, IL-4, IL-5 and IL-8, Akt is catalytically activated by phosphorylation at Thr308 and Ser478 (Alessi et al., 1996; Kohn et al., 1996; Stephens et al., 1998; Stokoe et al., 1997) . Activated Akt in turn phosphorylates downstream target molecules including Bad (del Peso et al., 1997) , caspase-9 (Cardone et al., 1998) , forkhead transcriptional factor (FKHR) (Biggs et al., 1999; Rena et al., 1999) , and GSK-3b (Pap and Cooper, 1998) , which promote induction of its anti-apototic eect. For example, IL-6 inhibits TGF-b-induced apoptosis via the PI3-K/Akt pathway in hepatoma cells (Chen et al., 1999) . IGF-1 activates PI3-K/Akt signaling (Alessi et al., 1996; Dudek et al., 1997; Mendez et al., 1996) ; and in MM cells, IGF-1 triggered PI3-K/Akt signaling protects against Dex-induced apoptosis (Ogawa et al., 2000) . To date IL-6 triggered Akt activation in MM cells has been implicated in proliferation independent of ERK signaling (Tu et al., 2000) , but the role of PI3-K/Akt signaling in mediating the growth, survival, and cell cycle regulatory eects of IL-6 in MM is not yet further elucidated.
In this study, we demonstrate that IL-6 triggers activation of PI3-K/Akt signaling in MM cells, and characterize its functional signi®cance. Our data suggest that PI3-K/Akt signaling mediates growth, protection against apoptosis, and cell cycle regulatory eects triggered by IL-6 in MM cells.
Results

IL-6 induces Akt phosphorylation in MM cells
We and others have previously shown that IL-6, which is a survival and anti-apoptotic factor in MM, stimulates Raf/MEK/MAPK and JAK/STAT3 pathways in MM cell lines and patient MM cells (CatlettFalcone et al., 1999; Ogata et al., 1997) . As can be seen in Figure 1a , low level constitutive phosphorylation of p-Akt, but not of STAT3 or p42/44 MAPK, was observed in MM.1S MM cells. IL-6 induced phosphorylation (Ser473) of Akt, as well as STAT3 and p42/44 MAPK, in MM.1S cells. This activation by IL-6 occurred as early as 5 min, and was dependent on the dose of IL-6 (Figure 1b ).
IL-6 stimulates Akt and its downstream targets via PI3-K activation
To further support IL-6 induced Akt activation, we next examined whether IL-6 also induced phosphorylation of known downstream kinases in the Akt signaling cascade. As can be seen in Figure 2 , constitutive phosphorylation of Bad and FKHR was noted in MM.1S cells. IL-6 (50 ng/ml) induced phosphorylation of Akt, Bad, GSK-3b and FKHR in a time dependent manner. Importantly, this induction of phosphorylation was inhibited by pre-treatment of MM.1S cells with the PI3-K inhibitor LY294002 (20 mM, 5 min) prior to IL-6 stimulation. In contrast, PTEN is constitutively expressed in MM.1S cells and unaected by IL-6 stimulation, and served as control for equal protein loading.
LY294002 inhibits IL-6 induced proliferation and MEK/MAPK signaling pathway in MM.1S cells
To study the biologic sequelae of Akt activation in MM cells, we next measured [ 3 H]TdR uptake of MM.1S cells in the presence of PI3-K inhibitor LY294002 and/or IL-6. We also used the MEK1 inhibitor PD98059 (25 mM), which inhibits growth signaling in MM cells (Hideshima et al., 2000a,b) . As can be seen in Figure 3a Figure  3a , IL-6 did not overcome the eect of 10 mM LY294002. These results suggested IL-6-induced cell proliferation is mediated via PI-3K, and that LY294002 induced G1 growth arrest.
To examine the eect of IL-6-induced PI3-K/Akt activation on MEK/MAPK or STAT3 signaling pathways, we further studied IL-6-induced activation of these kinases in MM.1S cells by Western blotting with phospho-STAT3, phospho-MEK1/2, and phosphop42/44 MAPK Abs, with or without PD98059 and/or LY294002. As can be seen in Figure 4a , both constitutive and IL-6 induced phosphorylation of Akt in MM.1S cells was inhibited by LY294002, but not by PD98059, pre-treatment. Constitutive p42/44 MAPK phosphorylation was inhibited by either PD98059 or LY294002. IL-6-induced activation of MEK1/2 and p42/44 MAPK, but not of STAT3, was inhibited by the MEK1 inhibitor PD98059. Importantly, IL-6 triggered phosphorylation of MEK1/2 and p42/44 MAPK, but not STAT3, was partially inhibited by LY294002 (Figure 4a ). Time course experiments revealed that IL-6-induced MEK1/2 and p42/44 MAPK phosphorylation at 5, 10 and 30 min was partially blocked by LY294002 and PD98059 ( Figure  4b ). These results suggest cross-talk between PI3-K/ Akt and MEK/MAPK signaling pathways triggered by IL-6.
IL-6 protects against Dex-induced apoptosis in MM.1S MM cells via PI3K activation and inhibition of caspase-9 activation
Our previous studies demonstrated that IL-6 inhibits apoptosis induced by Dex (Chauhan et al., 2000) , and that apoptosis triggered by Dex is mediated via caspase-9 activation . Since caspase-9 is a downstream target in Akt signaling, we next examined whether IL-6 could inhibit caspase-9 cleavage and apoptosis in MM.1S cells induced by Dex. As shown in Figure 5a To further con®rm a role for PI3-K in mediating the protective eect of IL-6 against Dex-induced apoptosis in MM cells, we examined the eect of IL-6-induced PI3-K activation on caspase-9 activity triggered during Dex-induced apoptosis in MM cells. Caspase-9 activity was measured using a colorimetric assay. As can be seen in Figure 5e , caspase-9 activity in MM.1S cells is increased by Dex treatment, and IL-6 inhibits this induction of caspase-9 activity (left panel). Importantly, LY294002 both augments caspase-9 activity induced by Dex and blocks the ability of IL-6 to downregulate Dex-induced caspase-9 activity (right panel). These results indicate that caspase-9 cleavage mediates Dex-induced apoptosis, that IL-6 inhibits apoptosis by blocking caspase-9 cleavage, and that LY294002 abrogates the protective eect of IL-6.
SHP2 is involved in PI3-K/Akt signaling pathway triggered by IL-6 in MM cells
We have previously shown that SHP2 mediates the protective eect of IL-6 against Dex-induced apoptosis (Chauhan et al., 2000) . Moreover, several reports have also demonstrated the interaction between gp130, JAK1 and PI3-K in LNCaP and PC-3 prostate cancer cell lines or cardiac myocytes after stimulation with IL-6 (Chung et al., 2000) or Leukemia inhibitory factor 
of three independent experiments
Oncogene IL-6 induced PI-3K/Akt signaling in MM T Hideshima et al (LIF) (Oh et al., 1998) . We therefore next examined whether IL-6 induced association of activated PI3-K with these molecules in MM.1S cells. Co-immunoprecipitation using anti-gp130, JAK1, JAK2, Tyk2 and SHP2 Abs before and after IL-6 treatment of MM.1S cells revealed that IL-6-induced co-precipitation of phosphorylated PI3-K with SHP2 (Figure 6a ), but not with anti-gp130, JAK1, JAK2, Tyk2 or PYK2 (data not shown). To examine the eect of LY294002 on co-precipitation of SHP2 and p85 PI3-K, as well as activation of SHP2, MM.1S cell were pre-treated with LY294002 (20 mM, 5 min), and then stimulated with IL-6. As can be seen in Figure 6b , LY294002 did not alter either co-precipitation of SHP2 and p85 PI3-K nor activation of SHP2, suggesting that SHP2 is an upstream molecule in PI3-K/Akt signaling triggered by IL-6.
Effect of IL-6-induced PI3-K activation on cell cycle profile in MM cells
Since previous reports have demonstrated that activated FKHR induces p27 KIP1 protein (Dijkers et al., 2000; Medema et al., 2000; Nakamura et al., 2000) and our data demonstrate that FKHR phosphorylation (inactivation) in MM.1S cells is triggered by IL-6 via PI3-K/Akt (Figure 2 ), we next examined the eect of PI3-K activation on the cell cycle pro®le in MM.1S cells, both in the presence or absence of IL-6. As can be seen in Figure 7a and Table 1 , IL-6 induces G1/S phase transition, LY294002 alone induces G1 growth arrest, and LY294002 blocks the G1/S transition induced by IL-6. Cell lysates of these same cells were subjected to Western blot analysis for p27 KIP protein expression. As shown in Figure 7b , IL-6 decreases and LY294002 increases p27 KIP1 protein expression in a time dependent fashion; p27 KIP1 induction by LY294002 is decreased by IL-6. No similar changes were observed in p21 protein status (data not shown).
Discussion
Interleukin-6 is the major growth and survival factor in human MM. Studies to date suggest that MEK/MAPK and JAK/STAT signaling pathways mediate cell proliferation and cell survival, respectively, via gp130 tyrosine phosphorylation (Berger et al., 1994; Nishimoto et al., 1994) . Although we and others have previously shown the protective eect of IL-6 against Figure 4 Eect of IL-6 induced PI3-K activation on MEK/MAPK and STAT3 signaling pathways in MM.1S cells (a) MM.1S cell were pre-treated with PD98059 (50 mM, 1 h) and/or LY294002 (20 mM, 5 min), stimulated with IL-6 (50 ng/ml, 5 min), and subjected to Western blotting using anti-phospho-Akt, Akt, phospho-STAT3, phospho-MEK1/2, phospho-p42/44 MAPK, or ERK2 Abs. (b) MM.1S cells pre-treated with PD98059 (50 mM, 1 h) and/or LY294002 (20 mM, 5 min) were stimulated with IL-6 (50 ng/ml for 0 ± 30 min) and subjected to Western blotting using anti-phospho-MEK1/2, phospho-p42/44 MAPK, and ERK2 Abs IL-6 induced PI-3K/Akt signaling in MM T Hideshima et al
Dex-induced apoptosis (Chauhan et al., 1997c (Chauhan et al., , 2000 Hardin et al., 1994; Lichtenstein et al., 1995; Xu et al., 1998) , the signaling pathway mediating this eect has not been delineated. In the present study, we show that IL-6 triggered PI3-K/Akt signaling in MM cells mediates: proliferation, associated with MEK/MAPK signaling cross talk; protection against Dex-induced apoptosis, associated with complex formation of SHP2 1S cells were cultured with Dex (1 mM) for 48 h in the presence or absence of IL-6 (50 ng/ml). Cells were harvested and subjected to agarose gel electrophoresis. (c) MM.1S cells treated with Dex (1 mM) for the times indicated were lysed and subjected to Western blot analysis using anti-procaspase-9, cleaved-caspase-9, procaspase-3, or cleaved caspase-3 Abs. (d) MM.1S cell were cultured with Dex (1 mM) for 36 h in the presence or absence of IL-6 (50 ng/ml). Cells were harvested, lysed, and subjected to Western blot analysis using anti-procaspase-9 or cleaved-caspase-9 Abs. (e) MM.1S cells were cultured for 48 h with DMSO (&), IL-6 (50 ng/ml, ), Dex (10 mM, ) or Dex+IL-6 ( ) in the presence or absence of LY294002 (5 mM). The cells were lysed, and caspase-9 activity was measured using a colorimetric assay and PI3-K, as well as inhibition of caspase-9 activity; and G1/S phase transition, associated with inactivation of FKHR and consequent lack of p27 KIP1 upregulation. Inhibition of these eects by LY294002 con®rmed the importance of PI3-K in mediating these biologic sequelae of IL-6. Our data therefore suggest that Akt signaling plays an integral role in the growth and survival eects of IL-6 in MM. Preliminary studies in our laboratory also demonstrate constitutive PI3K/Akt activation, as well as blockade of phosophorylation of PI3K/Akt and its downstream targets (Bad, FKHR and GSKb) by LY2940002, in IL-6 nonresponsive RPMI 8226 and U266 MM cells.
We ®rst demonstrated that IL-6, in a time and dose dependent fashion, triggered activation of Akt, p42/44 MAPK, and STAT3 in MM.1S cells. Phosphorylation of down-stream targets of Akt, including Bad, GSK3b, and FKHR, provided further support for IL-6-induced Akt signaling in these cells. Activation of both Akt and these downstream targets by IL-6 was blocked by LY294002, con®rming the role of PI3-K activation in Akt signaling. A recent report has also shown activation of Akt triggered by IL-6 in RPMI 8226 and OCI-My5 MM cells (Tu et al., 2000) ; however, IL-6 did not activate PI3-K in these lines, and Akt activation signals independent of PI3-K were therefore postulated.
To delineate the functional signi®cance of PI3K/Akt signaling in MM.1S cells, we ®rst examined its role in mediating proliferation. We have previously demonstrated that IL-6-induced proliferation is mediated via MAPK signaling, evidenced both by activation of the Ras Raf MEK/MAPK cascade (Ogata et al., 1997) , and by inhibition with the MEK1 inhibitor PD98059 (Hideshima et al., 2000b) . In this study, both constitutive and IL-6-induced DNA synthesis in MM.1S cells was inhibited by LY294002, and PD98059 enhanced this inhibitory eect. Consistent with this observation is our ®nding that LY294002 partially inhibits phosphorylation of p42/44 MAPK and MEK1/2 in MM.1S cells triggered by IL-6. These data therefore suggest cross talk between MEK/MAPK and Akt signaling pathways. On the other hand, PD98059 did not alter IL-6-induced STAT3 or Akt phosphorylation, nor did LY294002 aect IL-6 triggered STAT3 phosphorylation. Our results dier from a recent report in which inhibition of MM cell proliferation by PI3-K inhibition was not associated with a block in IL-6-dependent ERK activation (Tu et al., 2000) . However, this eect may be cell type-and stage of dierentiation-speci®c (Franklin and McCubrey, 2000) , since prior reports in HEK293 human embryonic kidney cells and C2C12 myoblast cells also demonstrate that activated Akt downregulates Raf phosphorylation, thereby inhibiting MEK/MAPK activation (Rommel et al., 1999; Zimmermann and Moelling, 1999) .
Upstream signaling between growth factor receptors and PI3-K is not fully delineated. IL-6 (Chung et al., 2000) or leukemia inhibitory factor (LIF) (Oh et al., 1998) have been reported to induce co-immunoprecipitation of gp130, JAK1 and PI3-K in LNCaP and PC-3 prostate cancer cell lines or cardiac myocytes. In the current study, we have therefore done co-immunoprecipitation studies with anti-gp130, JAK1, JAK2, Tyk2 and SHP2 Abs before and after IL-6 treatment of MM.1S cells: although IL-6 did not trigger association of phosphorylated p85 PI3-K with gp130, JAK1, JAK2, Tyk2, or PYK2, it did induce association of phosphorylated p85 PI3-K with SHP2. In Vero cells, Yart et al. (2001) have recently demonstrated that either LY294002 or dominant negative PI3-K blocked epidermal growth factor (EGF)-induced Ras activation, and that LY294002 also inhibited tyrosine phosphorylation of SHP2. In contrast, LY294002 did not have any eect on co-precipitation of SHP2 and p85 PI3-K or activation of SHP2 in MM.1S cells. Our data suggest a role for SHP2 in mediating IL-6 signaling between gp130 and PI3-K and provide further evidence for cross-talk between MEK/MAPK and PI3-K/Akt signaling. Ongoing studies in our laboratory are characterizing cross-talk between these cascades.
We next demonstrated that IL-6-triggered Akt signaling mediates a protective eect against Dexinduced apoptosis in MM cells. We have previously shown that Dex-induced apoptosis in MM cells occurs independent of cytochrome c release from mitochondria and is completely abrogated by IL-6 (Chauhan et al., 1997a,b,c) . Our subsequent studies showed that Dex-induced apoptosis is associated with the obligate activation of related activated focal tyrosine kinase, RAFTK (Chauhan et al., 1999) ; conversely, IL-6 confers its protective eect against Dex-induced apoptosis by activating SHP2, which binds and dephosphorylates RAFTK (Chauhan et al., 2000) . In Figure 6 IL-6 induces activation of SHP2 and its association with P85PI3K (a) MM.1S cells were stimulated with IL-6 (50 ng/ ml, 0 ± 10 min), lysed, and immunoprecipitated with anti-SHP2 Ab. Immune complexes were subjected to Western blotting using anti-phospho tyrosine, anti-p85 PI3-K, or anti-SHP2 Abs. (b) MM.1S cells pre-treated with either DMSO (0.04%) or LY294002 (20 mM) for 5 min were stimulated with IL-6 (50 ng/ml), lysed, and immunoprecipitated with anti-SHP2 Ab. Immune complexes were subjected to Western blotting using anti-phospho tyrosine or anti-p85 PI3-K Abs IL-6 induced PI-3K/Akt signaling in MM T Hideshima et al this study, we show not only that IL-6 induces p85 PI3-K/SHP2 signaling, but also that LY294002 inhibits activation of PI3-K and the protective eect of IL-6 against Dex-induced apoptosis. In this study, we further show that Dex-induced apoptosis is mediated via downstream caspase-9 activation and kinase activity, with resultant caspase-3 cleavage; and that IL-6 mediates its protective eect by inhibiting activation of caspase-9. Importantly, LY294002 blocks this downregulation of Dex-induced caspase-9 activity by IL-6. This inhibitory eect of Akt on caspase-9 activation could occur via two mechanisms: ®rst, Akt has been reported to regulate caspase activation at a premitochondrial level (Kennedy et al., 1999) ; alternatively, it could act at a postmitochondrial level, downstream of cytochrome c release and before activation of caspase-9 (Zhou et al., 2000) . Our prior studies have shown that Dex-induced apoptosis is not associated with cytochrome c release (Chauhan et al., 1997b) ; importantly, our recent studies implicate Smac release from mitochondria and caspase-9 activation in Dex-induced apoptosis . Taken together, these data con®rm a role for Akt/PI3-K signaling in the protection conferred by IL-6 against Dex-induced apoptosis: IL-6 stimulates SHP2 via gp130, which activates PI3-K; activated PI-3K induces downstream Akt activation, which in turn leads to caspase-9 inactivation and abrogation of Dex-induced Recent studies have shown that insulin-like growth factor (IGF) also induces proliferation and anti-apoptotic eects in MM, associated with p42/44 MAPK (Ferlin et al., 2000) and PI3-K/Akt (Ge and Rudiko, 2000) activation. IGF also inhibits Dexinduced apoptosis in MM cells via PI3-K/Akt signaling (Ogawa et al., 2000) ; however, whether IGF acts as demonstrated for IL-6 in our study is not yet de®ned. Finally, our study demonstrates that IL-6 induced Akt signaling in MM.1S cells mediates downstream phosphorylation (inactivation) of FKHR, with downregulation of p27 KIP1 and G1/S phase transition. Conversely, LY294002 blocked inactivation of FKHR, with consequent upregulation of p27 KIP1 and G1 growth arrest. This data is consistent with previous reports that inhibition of the PI3-K pathway induces p27 KIP1 and related cell cycle arrest (Collado et al., 2000) , and that forkhead proteins modulate cell-cycle progression by increasing p27 KIP1 expression (Dijkers et al., 2000; Medema et al., 2000; Nakamura et al., 2000) . Although previous reports have demonstrated that inactivation of PI3-K/Akt signaling by LY294002 inhibited p21 expression in A2780 ovarian cancer cell line (Mitsuuchi et al., 2000) , expression of p21 protein was not altered by LY294002 in our study.
In summary, our results demonstrate that PI3-K/Akt pathway plays a key role in proliferation, survival, and cell cycle regulation in MM cells. Further characterization of Akt signaling, including cross talk with other cascades, will not only elucidate molecular pathogenesis, but may also suggest targets for novel therapeutics.
Materials and methods
Cell culture
Human MM cell line MM.1S cells were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA). The cells were cultured in RPMI-1640 media containing 10% fetal bovine serum (FBS, Sigma Chemical Co., St. Louis, MO, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (GIBCO, Grand Island, NY, USA).
Western blot analysis
Serum-starved MM.1S cells were stimulated with IL-6, with or without LY294002 (Cell Signaling, Beverly, MA, USA) pre-treatment, washed once with ice-cold phosphate buered saline (PBS), and lysed in lysis buer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM NaF, 2 mM Na 3 VO 4 , 1 mM PMSF, 5 mg/ml leupeptine, 5 mg/ml aprotinin. The protein concentration of lysate was measured, mixed with gel electrophoresis loading buer, boiled for 5 min and subjected to SDS ± PAGE and Western blot analysis, as previously described (Hideshima et al., 2000a) . Speci®c proteins were immunoprecipitated from cell lysates by overnight incubation at 48C with the indicated Abs. Protein A-Sepharose CL-4B (Pharmacia) beads were added and incubated for 2 additional hours at 48C. The beads were then washed three times with lysis buer, resuspended in gel electrophoresis loading buer, and boiled for 5 min. Immunoprecipitates were subjected to SDS ± PAGE and Western blot analysis. Anti-phospho-Akt (Ser473), Akt, phospho-MAPK, phospho-STAT3, phosphoBad (Ser136), phospho-GSK-3b (Ser9), phospho-FKHR (Ser256), PTEN, and phospho-MEK1/2 Abs were purchased from Cell Signaling (Beverly, MA, USA). Anti-ERK2, SHP2, and p27 Abs were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA); and anti-p85 PI3-K Ab was purchased from Upstate Biotechnology (Lake Placid, NY, USA).
DNA synthesis
Proliferation was measured as previously described (Hideshima et al., 2000a 
Assays of apoptosis
MM.1S cells were cultured in the presence of Dex (1 mM) at 378C for the indicated intervals. To assay for apoptosis, genomic DNA extracted using a genomic DNA puri®cation kit (Promega, Madison, WI, USA) was electrophoresed on 2% agarose gel containing 5 mg/ml of ethidium bromide and analysed under UV light for DNA fragmentation, as in prior studies . Cleavage of caspase-9 and caspase-3 were also performed by Western blotting using anti-cleaved caspase-9 (Cell Signaling), caspase-9 (Santa Cruz), and caspase-3 (Pharmingen, San Diego, CA, USA) Abs.
Caspase-9 colorimetric assay
Caspase-9 colorimetric assay was performed to assess caspase-9 activity after treatment of MM.1S cells with Dex and/or LY. MM.1S cells were cultured in the presence of Dex (1 mM), LY (5 mM) and/or IL-6 (100 ng/ ml) for 36 h at 378C. Cells were then lysed by lysis buer and subjected to colorimetric assay according to manufacture's protocol (R&D System, Minneapolis, MN, USA). 
Cell cycle analysis
MM cells cultured for 0, 6, 12 and 24 h in LY (10 mM) or control media (0.01% DMSO) in the presence or absence of IL-6 (50 ng/ml) were harvested, washed with PBS, ®xed with 70% ethanol, and treated with 10 mg/ml of RNase (Roche Diagnostics Corp., Indianapolis, IN, USA). Cells were then stained with propidium iodine (PI, Sigma) (5 mg/ml), and cell cycle pro®le was determined using the program M software on an Epics¯ow cytometer (Coulter Immunology, Hialeah, FL, USA), as in prior studies (Hideshima et al., 2000a) .
